Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWiTCH: Hydroxyurea vs Transfusions for Secondary Stroke Prevention in Sickle Cell Anemia
NCT00122980Phase 3Terminated
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 2006
- Primary completion
- Jun 2010
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxyurea in sickle cell anemia (SCA), stroke and iron overload (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Occurrence of an Adjudicated Secondary Stroke at 30 months and Liver Iron Content Change-from-baseline at 30 months. Started Oct 2006; status: terminated.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)strokeiron overload
Beyond the preview
Go deeper on NCT00122980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122980.